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Introduction  
Colorectal cancer (CRC) is the third leading cause of death in Europe owing to metastatic spread. 
Tumor dissemination occurs via 2 main routes: a systemic route through the bloodstream leading 
to liver or lung metastases and a local route through the peritoneal cavity. The current concept of 
potentially curative treatment for metastatic CRC (mCRC) combines the treatment of 
microscopic disease using chemotherapy with surgical resection of macroscopic disease. This 
combined modality approach offers long-term survival and even cures in some cases, and it 
represents the standard of care for mCRC.  
The natural history of mCRC with peritoneal metastases is different from mCRC involving other 
systemic sites. Metastatic peritoneal disease is associated with worse survival when compared 
with other metastatic sites even after complete surgical resection, and this poor outcome is 
explained by a limited response to systemic chemotherapy. The COMBATAC trial (A 
prospective multicenter phase II study evaluating multimodality treatment of patients with 
peritoneal carcinomatosis arising from appendiceal and colorectal cancer) presented by Glockzin 
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et al aimed to determine the impact of perioperative systemic chemotherapy plus targeted 
therapy using cetuximab on outcomes after potentially curative cytoreductive surgery for 
peritoneal metastases from CRC.  
Discussion  
The goal of this trial was noteworthy as it hoped to better define the most effective perioperative 
management for peritoneal mCRC. Unfortunately, despite an appropriate study design, the trial 
ended prematurely owing to poor patient enrollment. However, this report by Glockin et al is 
important as it highlighted once again the critical impact of multimodality treatment concept for 
potentially curative treatment of peritoneal metastases combining systemic chemotherapy and 
complete surgical resection.  
Associated with surgery, systemic chemotherapy was shown to be a major positive prognostic 
factor for a curative outcome. However, the most appropriate chemotherapy regimen before 
and/or after surgery remains still in question. When proposed before surgery, pathologic 
response should be evaluated because it is an important prognostic factor. Another argument 
favoring preoperative chemotherapy is the morbidity associated with cytoreductive surgery, 
which could preclude or postpone return to adjuvant chemotherapy. With respect to perioperative 
chemotherapy, no regimen has demonstrated a clear clinical benefit, but oxaliplatin-based 
chemotherapy for 4 to 6 preoperative cycles has received the most attention. However, increased 
morbidity after cytoreductive surgery has been associated with anti-vascular endothelial growth 
factor therapy. For patients with response or stable disease after preoperative chemotherapy, 
cytoreductive surgery should be considered. Owing to the lower efficacy of systemic 
chemotherapy on peritoneal metastases, peritoneal progression is not a formal contra-indication 
for surgery, when systemic disease is controlled.  
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Postoperative adjuvant chemotherapy is also an important issue to consider, and the general 
recommendation is to resume the same chemotherapy within 8 weeks after surgery when feasible 
to complete a goal of 12 perioperative cycles. Randomized controlled trials are currently lacking 
to better determine the most appropriate perioperative management for patients with peritoneal 
metastasis of CRC. However, several arguments exist to consider perioperative chemotherapy as 
the standard of care.  
When complete cytoreduction can be achieved, surgery is the only definitive treatment that 
offers a positive long-term outcome or even cures for patients with peritoneal metastasis from 
CRC. Cytoreductive surgery is a demanding treatment, and patient selection is pivotal. A recent 
colonoscopy is required before surgery in order to rule out the presence of second colon cancer 
localization (around 10% of patients). Peritoneal metastases must be proven either on pathology 
or from medical history with a typical lesion on imaging. A computed tomography is mandatory 
to allow for detection of both peritoneal and extraperitoneal disease. Considering the relatively 
low sensitivity of computed tomography and magnetic resonance imaging for the diagnosis of 
peritoneal metastases, an exploratory laparoscopy with peritoneal biopsies should be considered 
to confirm peritoneal metastases and evaluate resectability. The 2 main prognostic factors after 
cytoreductive surgery for peritoneal metastases of CRC are completeness of cytoreduction based 
on completeness of cytoreduction (CC) score (CC-0, no residual nodules; CC-1, residual nodes < 
2.5 mm; CC-2, residual nodules < 25 mm; and CC-3, > 25 mm), and extent of peritoneal 
metastases based on Peritoneal Cancer Index (PCI). Improved outcomes are expected with 
complete cytoreductive surgery (CC-0), and PCI < 7. Moreover, when complete cytoreductive 
surgery is considered, the only surgical approach should be open laparotomy because 
laparoscopic exploration significantly underestimates the extent of peritoneal spread. In 1989, 
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Paul Sugarbaker proposed hyperthermic intraperitoneal chemotherapy (HIPEC) to treat 
microscopic peritoneal disease. The rationale for this approach was to increase peritoneal 
concentration of chemotherapy and improve its cytotoxic effects by hyperthermia. At the time, it 
was reasoned that peritoneal metastases presented with poorer prognoses than systemic 
metastases with a greater than 50% risk of peritoneal recurrence; HIPEC was implemented with 
the goal of improving local control. Since 1989, several retrospective studies and one 
randomized control trial demonstrated the positive effect of combined cytoreductive surgery and 
HIPEC on survival for patients with peritoneal metastases from CRC. However, the specific 
impact of HIPEC has not been clearly established. The French PRODIGE 7 trial (Perioperative 
outcomes of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy versus 
cytoreductive surgery alone for colorectal peritoneal carcinomatosis: PRODIGE 7 randomized 
trial; NCT00769405) recently presented the results of a multi-institutional randomized controlled 
trial to determine the impact of HIPEC using oxaliplatin in the management of peritoneal 
metastases from CRC.  
The goal of this clinical study was to compare the clinical efficacy of complete cytoreductive 
surgery with complete cytoreductive surgery with HIPEC using oxaliplatin in patients with 
metastatic peritoneal disease. In this trial, 60-day morbidity was significantly higher in the 
HIPEC group (24.1% vs. 13.6%; P = .030), and this combined approach was associated with an 
increased length of hospital stay. In terms of clinical efficacy, the investigators reported 41.7 and 
41.2 months of median overall survival in the HIPEC and non-HIPEC groups, respectively ( P 
= .995). In a subset of patients with PCI between 11 and 15, HIPEC seemed to provide clinical 
benefit as recurrence-free survival was 13.1 and 11.1 months in the HIPEC and non-HIPEC 
groups, respectively ( P = .486). This study concluded that the addition of oxaliplatin-HIPEC to 
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complete cytoreductive surgery did not influence survival. These results questioned the interest 
of oxaliplatin-HIPEC in the management of peritoneal metastases for CRC. Considering the high 
rate of peritoneal recurrence after complete cytoreductive surgery, the limited effect of systemic 
chemotherapy, and the poorer prognosis of peritoneal metastases from CRC, increasing local 
control is a major challenge! Based on the results provided in liver metastases by hepatic intra-
arterial chemotherapy, intraperitoneal therapy should still be considered as part of the treatment 
algorithm.  
Conclusion  
Global efforts continue to focus on identifying the most appropriate management of peritoneal 
metastases from CRC, and it is critical that local therapy must be considered integral to improve 
local control. It is clear that the effectiveness and safety of complete macroscopic surgical 
resection of mCRC is becoming a reality in the modern era. However, the treatment of 
microscopic mCRC remains an on-going challenge both with respect to its diagnosis and 
treatment. Although there have been significant advances in the perioperative management and 
systemic therapy of mCRC, the same type of improvements continue to be urgently needed for 
metastatic peritoneal disease.  
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